Vasodilatory prostaglandins play a key role in neurovascular coupling (NVC),
Introduction
Neurovascular coupling (NVC), the tight link between neuronal activity and local cerebral blood flow, is essential for normal brain function. It is also the physiological basis of functional brain imaging techniques, such as positron emission tomography and functional magnetic resonance imaging that are widely used to map neuronal activity using hemodynamic signals (Fox et al., 1988; Logothetis et al., 2001; Lauritzen, 2005) . In several pathologies including Alzheimer's disease and stroke, NVC is altered by dysfunction in the neuronal, astroglial, and/or vascular compartments of the neurovascular unit Zlokovic, 2011) .
Despite this physiopathological importance the cellular and molecular mechanisms of NVC remain elusive. In the neocortex they involve various messengers Leithner et al., 2010; Liu et al., 2012) . In rodents, vasodilatory prostaglandins play a key role in NVC accounting for approximately one-half of the hyperemic response to sensory stimuli (Niwa et al., 2000; Bakalova et al., 2002; Stefanovic et al., 2006; Lecrux et al., 2011) . Prostaglandins are arachidonic acid derivatives produced by the sequential action of rate-limiting cyclooxygenases (COXs) and terminal synthesizing enzymes specifying their nature (Funk, 2001) . Presumably because of the lack of selective inhibitors for terminal enzymes, most studies relied only on inhibiting COX-1 and/or COX-2 activity (Niwa et al., 2000 (Niwa et al., , 2001 Bakalova et al., 2002; Zonta et al., 2003; Stefanovic et al., 2006; Takano et al., 2006; Gordon et al., 2008; Lecrux et al., 2011) , hence lacking determination of the prostaglandin subspecies relevant for NVC.
In the cerebral cortex prostaglandin E2 (PgE 2 ) and prostacyclin (PgI 2 ) are the main prostaglandins relaxing vascular smooth muscle cells and pericytes through activation of EP2, EP4, or IP receptors (Davis et al., 2004; Maubach et al., 2009; Myren et al., 2010 Myren et al., , 2011 Woodward et al., 2011; Hall et al., 2014) . Although antagonism of these receptors provides a means to identify the NVC prostaglandins, their use is still poorly documented (Hall et al., 2014) and has been limited by the confounding constrictive effect of the PgE 2 receptor EP1 (Dabertrand et al., 2013) .
The cellular sources of the NVC prostaglandins are also uncertain since different synthesizing enzymes are expressed in various cell types including neurons, astrocytes, microglia, and endothelial cells (Yamagata et al., 1993; Breder et al., 1995; Kaufmann et al., 1996; Mehl et al., 1999; Vazquez-Tello et al., 2004; Wang et al., 2005; Cahoy et al., 2008; Anrather et al., 2011; Lecrux et al., 2011) .
We addressed these issues using ex vivo and in vivo approaches, and found that COX-2 and the PgE 2 receptors EP2 and EP4 are essential contributors of NVC responses in the cerebral cortex. Consistently we demonstrate the PgE 2 release ex vivo by means of liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS). Using immunocytochemistry and single-cell reverse transcriptase-PCR (scRT-PCR), we established that pyramidal cells are the major cell type equipped for COX-2-derived PgE 2 synthesis. We further demonstrated their central role by concurrent in vivo optogenetic photostimulation of pyramidal cells and pharmacological manipulations of the NVC response. Our findings identify pyramidal cells and PgE 2 , respectively, as the major source and key vasoactive messenger of NVC responses to sensory stimulation.
Materials and Methods
Animals. Wistar rats (postnatal days 17.0 Ϯ 0.1; Janvier) were used for patch-clamp recordings, vascular reactivity and measurement of prostanoids in acute slices. Adult Wistar or Sprague-Dawley rats (250 -300 g) were respectively used for immunostaining (n ϭ 7) or whisker-induced NVC experiments (n ϭ 15). The Jackson Laboratory Line B6;129P-Emx1 tm1Jlr /J (Gorski et al., 2002) mice were crossed with B6;129S-Gt(ROSA)26Sor tm32.1(CAG-COP4*H134R/EYFP)Hze /J mice (Madisen et al., 2012) . Five male and female 2-to 4-month-old animals from the resultant strain weighing 20 -30 g were used for optogenetic experiments. B6. 2Jrs/J mice (Feng et al., 2000) of the same age and weight were used for controls (n ϭ 4). All animals were housed in a temperature-controlled (21-25°C) room under daylight conditions and were given water ad libitum. A maximum of five mice or three rats are housed per cage and single animal housing was avoided. All experiments were performed in accordance with the EU Council Directive 86-609, the British Columbia Animal Care Committee and animal and Ethics committee of the Montreal Neurological Institute in accordance with Canadian Council for Animal Care guidelines.
Slice preparation. After decapitation brains were quickly removed and placed into cold (ϳ4°C) oxygenated artificial CSF (aCSF) containing the following (in mM): 126 NaCl, 2.5 KCl, 1.25 NaH 2 PO 4 , 2 CaCl 2 , 1 MgCl 2 , 26 NaHCO 3 , 10 glucose, 15 sucrose, and 1 kynurenic acid (SigmaAldrich). For patch-clamp recordings and vascular reactivity rat coronal slices (300 m thick) containing the barrel cortex were cut with a vibratome (VT1000S; Leica) and allowed to recover at room temperature for at least 1 h in aCSF saturated with O 2 /CO 2 (95%/5%) as previously described (Karagiannis et al., 2009 ). Slices were then transferred to a submerged recording chamber and perfused with oxygenated aCSF lacking kynurenic acid. Blood vessels and cells were first visualized in the slice under infrared (IR) illumination, using 60ϫ (LUMPlan FL/IR 60ϫ/0.90 W) or 40ϫ (LUMPlan FL N 40ϫ/0.80 W) objectives attached to BX51WI (Olympus) or SliceScope (Scientifica) microscope equipped with Dodt gradient contrast optics (DGC; Luigs and Neumann; Dodt and Zieglgansberger, 1998) and collimated light emitting device (LED; 780 nm, ThorLabs) as transmitted light sources. For prostaglandins and thromboxane analysis, parasagittal slices (400 m thick) were microdissected to isolate the sensorimotor cortex and the underlying white matter.
Vascular reactivity. Diving arterioles in layers I-III were selected under IR-DGC videomicroscopy on the basis of their well defined luminal diameter (10 -30 m), their length remaining in the focal plane for at least 50 m Rancillac et al., 2006) and of the thickness of their wall (4.6 Ϯ 0.2 m, n ϭ 89 arterioles; Table 1 ) indicative of the presence of smooth muscle cells (Girouard et al., 2010) . A resting period of at least 30 min (Lovick et al., 1999; Zonta et al., 2003) was observed after slice transfer. To limit the temperature-dependent toxicity of NMDA in slices (Andrew et al., 1996) images were acquired at room temperature every 10 s using a digital CCD camera (CoolSnap HQ2, Roper Scientific, or QIClick, QImaging) and Imaging Workbench 6.0.25 (INDEC BioSystems) or Image Pro Plus 6.3.1 (MediaCybernetics) software. The focal plane was maintained constantly on-line using parenchymal cells as anatomical landmarks. To compensate for potential x-y drifts all images were realigned off-line using the "StackReg" plug-in (Thévenaz et al., 1998) of ImageJ 1.48 software. Luminal diameter was measured on registered images using custom analysis software developed in MATLAB (MathWorks). To ovoid potential drawbacks due to blood vessels instability, only arterioles exhibiting a stable luminal diameter were further taken into account. Arterioles were considered stable if the relative SD (RSD) of their luminal diameter during an initial baseline period of 5 min was Ͻ5%. Because arterioles have a limited myogenic tone in brain slices (Fergus and Lee, 1997; Lovick et al., 1999; Cauli et al., 2004; Rancillac et al., 2006; , blood vessels were preconstricted by superfusing the thromboxane A2 agonist, 9,11-dideoxy11a,9a-epoxymethanoprostaglandin F2␣ (U46619; 50 -75 nM). As the degree of vasoconstriction has been reported to influence the amplitude and polarity of vascular responses (Blanco et al., 2008) , only arterioles developing a similar and stable vasoconstriction (Ϫ40.6 Ϯ 1.5% of initial diameter, RSD Ͻ10%, n ϭ 89 arterioles; Table 1 ; Movie 1) within the 40 min following U46619 application were included in the analysis. NMDA (30 M) was bath-applied for 5 min after 60 min of U46619 superfusion (Movie 1). COX-1/2 inhibitors and prostaglandin receptor antagonists were applied 30 min before NMDA application and throughout all the duration of the experiment. Tetrodotoxin (TTX) was applied 15 min before NMDA application. Only one arteriole was monitored per slice. Dilatory responses are expressed as changes relatively to the preconstricted state. The magnitude (Bakalova et al., 2002) of vasodilations was defined as the integral of diameter changes measured for a period of 1000 s following the onset of vasodilation.
Analysis of prostaglandins and thromboxane: collection of supernatants and slices. Four acute slices and a control slice were placed in two wells of a 12-well plate filled with 1 ml of oxygenated aCSF containing 50 nM U46619 and a mixture of O 2 /CO 2 (95%/5%) was continuously delivered. After an equilibration period of 30 min, 100 l of supernatant were collected and rapidly frozen in dry ice (t ϭ Ϫ30 min). One-hundred microliters of SC 560, NS 398 or their vehicle (DMSO 0.02%) were then added to the medium. After 30 min of incubation 100 l of supernatant were collected, rapidly frozen in dry ice (t ϭ 0 min), and replaced by a solution supplemented with NMDA or its vehicle (water). After 2 and 5 min of incubation 100 and ϳ900 l were, respectively, collected, frozen, and replaced by 1 ml of aCSF containing COX-inhibitor or its vehicle but lacking NMDA. One-hundred microliters of supernatant were collected 5 min and 15 min after NMDA washout (t ϭ 10 and 20 min, respectively). After 25 min, all of the remaining supernatant (i.e., ϳ800 l) was collected and frozen as well as the four slices. Viability of slices after treatment was evaluated by ensuring that the control slice displayed numerous healthy-looking cells when observed under IR-DGC illumination.
Analysis of prostaglandins and thromboxane: equipment. Lipid analysis was performed using LC-ESI-MS/MS. The LC-MS/MS system consisted of a hybrid triple quadrupole-ion trap QTrap 5500 mass spectrometer (AB Sciex) equipped with a Turbo-V-source operating in negative ESI mode, an Agilent 1200 binary HPLC pump, column oven (40°C) and degasser (Agilent) and an HTC Pal autosampler (Chromtech) with a cooling stack which kept the samples at 4°C. High-purity nitrogen for the mass spectrometer was produced by a NGM 22-LC/MS nitrogen generator (Cmc Instruments).
Analysis of prostaglandins and thromboxane: extraction and mass spectrometry. Analysis of prostaglandin content was performed as previously described (Schmitz et al., 2014) . The homogenized tissue pieces and the slice supernatants were extracted by two rounds of liquid-liquid extraction with ethylacetate (600 l). The samples were spiked before extraction with the internal standard mixture, 100 l of 0.15 M EDTA and 10 l BHT (2 mg/ml in methanol) to prevent oxidation of analytes. After vortexing and centrifugation for 3 min at 17,000 ϫ g, the organic fractions were combined and evaporated at a temperature of 45°C under a gentle stream of nitrogen.
LC-MS/MS conditions. For the chromatographic separation a Synergi Hydro-RP column and precolumn were used (150 ϫ 2 mm I.D., 4 m particle size and 80 Å pore size from Phenomenex). A linear gradient was used at a flow rate of 300 l/min. The mobile phase A was water/formic acid (100:0.0025, v/v, pH 4.0) and mobile phase B acetonitrile/formic acid (100: 0.0025, v/v). The sample solvent was acetonitrile/water/formic acid (20:80: 0.0025, v/v, pH 4.0) . The total run time was 16 min and injection volume 45 l. Retention times of 6-keto-PgF 1␣ , TXB 2 , PgF 2␣ , PgE 2 , and PgD 2 were 7. 4, 8.0, 8.2, 8.7, and 9 .2 min, respectively.
The mass spectrometer was operated in the negative ion mode with an electrospray voltage of Ϫ4500 V at 450°C. Quantification. Concentrations of the calibration standards, quality controls, and unknowns were evaluated by Analyst software (v1.5; B Sciex). Ratios of peak areas of the lipid and the respective internal standard (y-axis) were plotted against concentration (x-axis) and calibration curves for each lipid were calculated by least-square regression analysis with 1/concentration 2 weighting. Variations in accuracy and intraday and interday precision (n ϭ 6 for each concentration, respectively) were Ͻ15% over the respective ranges of calibration (0.02-250 ng/ml for PgE 2 , PgD 2 and 6keto-PgF 1␣ ; 0.075-250 for TXB 2 and 0.08 -1000 for PgF 2␣ ).
Astrocytes vital staining. Slices were vitally stained by a 20 min superfusion of aCSF containing 1 M sulforhodamine 101 (SR101, SigmaAldrich) or 2 M TexasRed hydrazide (TxRed; Invitrogen) and rinsed for at least 10 min (Lecrux et al., 2011) . SR101 and TxRed were excited at 535 nm with a LED (CoolLED, Precise Excite) and red fluorescence was collected using a Triple-beamsplitter 395/495/610 (FF395/495/610-Di01-25x36, Semrock) and a Tripleband emission filter 425/527/685 (FF01-425/527/685-25, Semrock). IR-DGC and fluorescent Images were captured with a digital CCD camera (CoolSnap HQ2) and Imaging Workbench 6.0.25 software.
Whole-cell recordings. Patch pipettes (5.5 Ϯ 0.1 M⍀) pulled from borosilicate glass were filled with 8 l of RNase free internal solution containing the following in (mM): 144 K-gluconate, 3 MgCl 2 , 0.5 EGTA, 10 HEPES, pH 7.2 (285/295 mOsm). Whole-cell recordings were performed at 27.0 Ϯ 0.5°C using a patch-clamp amplifier (Axopatch 200B, MDS). Data were filtered at 5-10 kHz and digitized at 50 kHz using an acquisition board (Digidata 1440, MDS) attached to a personal computer running pCLAMP 10.2 software package (MDS).
Electrophysiological properties were determined in voltage-clamp mode for astrocytes (Houades et al., 2008; Lecrux et al., 2011) and current-clamp mode for neurons (Karagiannis et al., 2009) . Membrane potential values were not corrected for liquid junction potential. Input resistance of astrocytes was determined by plotting a voltage/current curve of the current response at steady state. This resistance was corrected for series resistance determined by plotting a voltage/current curve of the capacitive transients (Houades et al., 2008) . Resting membrane potential of astrocytes was determined by calculating the intercept of the voltage/current curve with the 0 pA value. Resting membrane potential of neurons was measured just after passing in whole-cell configuration. Only neurons with a resting membrane potential more negative than Ϫ51 mV were analyzed further. Thirty-two electrophysiological properties chosen to describe the electrophysiological diversity of cortical neurons (Ascoli et al., 2008) were determined as previously described (Karagiannis et al., 2009 ) using custom analysis software developed in MATLAB (MathWorks).
Morphological analysis of IR-DGC images. Arteriole wall thickness was measured manually using Image-Pro Analyzer 7.0.0.951 software (Media Cybernetics). Somatic features were measured from IR-DGC images of the recorded cells as previously described (Karagiannis et al., 2009) . Briefly, the soma was manually delineated using Image-Pro Analyzer 7.0.0.951 software. Then, the length of major and minor axes, the perimeter, and the area were extracted. The soma elongation was calculated as the ratio between major and minor axes. Roundness was calculated according to: perimeter 2 4 ϫ area A value close to 1 is indicative of round somata. Somata with no obvious process and displaying a roundness value lower than 1.5 was considered as round. Cells with a soma exhibiting two processes in opposite direction were defined as fusiform if their elongation was Ͼ2 . If it was Ͻ2, cells were considered as ovoid. Cells whose soma had Ͼ2 processes were defined as irregular.
Cytoplasm harvest and scRT-PCR. At the end of the whole-cell recording lasting Ͻ20 min, the cytoplasmic content was aspirated in the recording pipette. The pipette's content was expelled into a test tube and RT was performed in a final volume of 10 l, as described previously (Lambolez et al., 1992) . Two scRT-PCR protocols were designed to probe simultaneously for the expression of prostaglandin synthesizing enzymes and well established markers of cortical astrocytes (Houades et al., 2008) or neurons (Ascoli et al., 2008; Karagiannis et al., 2009 ). Prostaglandinsynthesizing enzymes included COX-1 and COX-2, the terminal PgE 2 synthases (PGES); mPGES1, mPGES2, and cPGES, and PgI 2 synthase (PGIS). Astrocytes markers included S100␤ and glial fibrillary acidic protein (GFAP). Neuronal markers included the vesicular glutamate transporter, vGluT1, the two isoforms of glutamic acid decarboxylase (GAD65 and GAD67), the neuronal isoform of nitric oxide synthase (NOS-1), calbindin (CB), calretinin (CR), parvalbumin (PV), neuropeptide Y (NPY) or vasoactive intestinal polypeptide (VIP), somatostatin (SOM), and cholecystokinin (CCK). Two-steps amplification was performed essentially as described previously using the primer pairs listed in Table 2 . Ten microliters of each individual PCR product were run on a 2% agarose gel stained with ethidium bromide using ⌽X174 digested by HaeIII as a molecular weight marker.
Double-fluorescence labeling. Rats were deeply anesthetized with sodium pentobarbital (50 mg/kg, i.p.) and their brain were perfusion-fixed (500 ml of ice-cold 4% paraformaldehyde (PFA), in 0.1 M phosphate buffer, pH 7.4), and postfixed by immersion in 4% PFA (2 h, 4°C). Brains were then cut in 50-m-thick coronal sections with a HM 650V vibratome (Microm). Sections from three to four different rat brains were simultaneously incubated overnight with the primary antibodies against COX-2 and specific markers. NVC to whisker stimulation using laser Doppler flowmetry (LDF). Rats were anesthetized (urethane, 1 g/ml, i.p.), cannulated in the femoral artery for blood gas and blood pressure measurements, and placed in a stereotaxic frame (David Kopf Instruments). Body temperature was maintained at 37°C using a rectal probe connected to a homeothermic blanket (Harvard apparatus). The posterior atlanto-occipital membrane was exposed for intracisternal injection (3 l, 1 l/min) of vehicle and drugs using a 30 G needle connected to a 10 l Hamilton syringe driven by a Harvard infusion pump, as previously described (Lecrux et al., 2011) . All drugs effects were measured on whisker stimulation at 20 min after intracisternal injection. CAY 10441 and its vehicle slightly, but significantly, affected baseline blood flow. Left whiskers were trimmed, attached to a glass capillary connected to a Piezo actuator (Piezo Systems) placed in a Faraday cage and driven by an isolated pulse stimulator (8 Hz, A-M Systems, Model 2100) controlled by PowerLab (AD Instruments). Seven stimulation blocks (40 s baseline, 20 s stimulation) were given for each condition (control, vehicle, and drug) with only one drug being tested in each rat. The skull over the right barrel cortex was thinned to translucency for positioning of the laser-Doppler probe (wavelength: 785 nm, 0.58 mm diameter, 0.5 mm transmit/receive spacing, Transonic Systems). Following placement of the laser Doppler probe over the most responsive region of the barrel cortex, a tungsten microelectrode (FHC) was inserted using stereotaxic manipulators with an angle (40°) in the cortical depth (1 mm) as close as possible (Ϯ1.5 mm) of the LDF probe for simultaneous local field potential (LFP) recordings and another microelectrode was positioned symmetrically in the corresponding ipsilat- eral barrel cortex. Recordings of LFPs were performed through a 2-channel amplifier (A-M Systems, model 1800), a reference screw being placed on the dura over the frontal cortex. Electrophysiological data were filtered (10 -500 Hz), amplified and acquired at 10 kHz through a PowerLab (AD Instruments) and analyzed using script written in MATLAB (MathWorks). LDF data were extracted for every second using LabChart software (AD instruments), and whisker-evoked cerebral blood flow (CBF) changes over baseline for the seven stimulation blocks were averaged. LFPs on the contralateral and corresponding ipsilateral barrel cortex were averaged every 125 ms for each 20 s stimulation, and the LFP amplitude, defined as the difference between the maximal and minimal values, was averaged over the repeated blocks and normalized from control condition. Laser-speckle contrast imaging and optogenetic stimulation. Mice were anesthetized with 5% isoflurane in air, and then reduced to 1-1.5% during surgery. Body temperature was maintained at 37 Ϯ 0.5°C by a heating pad which had its intensity controlled by temperature feedback from a rectal probe. The mouse was secured in a custom-made head hold using cyanoacrylate and dental cement and a craniotomy was made over the right forelimb sensorimotor cortex. The dura was left intact. Agarose dissolved in HEPES buffered aCSF, pH 7.3, to 1.5% was placed over the surface of the cortex at 37°C. The surface of the cortex was then covered with a no.1 130, 160 m thick glass coverslip. Before imaging, the brain was warmed to ϳ37°C by pumping warm water through tubing attached to the custom built stainless steel head hold (Xie et al., 2013) . During stimulation procedures anesthesia was switched to a ketamine/xylazine combination (100/10 mg/kg) that was supplemented as required.
The surface of the cortex was illuminated with a 784 nm 32 mW StockerYale SNF-XXX_885 s-35 laser (Stocker and Yale) with a beam expander directed at the cortex at a 30°a ngle. Light intensity was controlled with a polarizer. The flow of blood cells and resultant blurring in the interference patterns (Briers, 2001 ) was detected by a CCD camera (Dalsa 1M60). Image acquisition was performed using EPIX XCAP software (v2.2). Ten trials for each stimulation parameter consisting of 100 -130 frames were acquired at 10 Hz with a 10 ms exposure time. Using MATLAB (MathWorks) each 1024 ϫ 1024 pixel image in the stack was variance filtered spatially with a kernel size of 3 pixels. Blood flow measurements were estimated as the inverse square of speckle contrast values which were scaled between minimum and maximum flow rate (Cheng and Duong, 2007) . Minimum flow was determined from contrast values measured from the mouse cortex after the animal was killed. For stimulation a 473 nm laser beam (Crystalaser, collimated to ϳ100 m diameter, 5 ms pulses, 3.3 mW, 100 Hz, 1 s) was targeted to forelimb sensorimotor cortex (Scott and Murphy, 2012) . Light from the 473 nm laser was blocked from contaminating the speckle signal as detected by the camera by a 715 nm long-pass filter. Regions of interest selected for assessment of speckle contrast over time were 1 mm 2 and centered at the site where the laser was targeted over the cortex.
After baseline assessment of light-evoked hemodynamic responses the agarose was removed from the cortical surface and NS 398 was administrated directly on the cortex for 30 min. Agarose was then reapplied to the cortex (37°C), covered with a coverslip, and laser speckle contrast imaging ensued. The magnitude of CBF change was defined as the integral of CBF changes measured from the onset of stimulation to the end of the recording.
Drugs. U46619, NMDA, SC 560, NS 398, AH 6809; and L 161-982 were purchased from Enzo Life Sciences, CAY 10441 from Cayman chemical, Indomethacin from Sigma-Aldrich and TTX from Latoxan.
Statistical analyses. Statistical analyses were performed with Prism4 (GraphPad Software) or Statistica 6 (Statsoft). All values are expressed as mean Ϯ SEM. Normality of distributions and equality of variances were assessed using the Shapiro-Wilk test and the F test, respectively. Parametric tests were only used if these criteria were met. Bonferroni correction was used for multiple comparisons. Statistical significance on all figures uses the following convention: *p Ͻ 0.05, **p Ͻ 0.01, ***p Ͻ 0.001.
Statistical significance of vascular responses, morphological and electrophysiological properties, and light-induced CBF responses between Thy1-YFP and Emx1-Cre;Ai32 mice was determined using the MannWithney U test. Comparison of the occurrence of expressed genes between different cell types was determined using Fisher's exact test. Under control conditions (Ctrl, black, n ϭ 16 arterioles from 12 rats) NMDA induces vasodilations. Nonselective COX-1/2 inhibition by indomethacin (Indo; magenta, n ϭ 6 arterioles from 3 rats) dramatically reduced the vascular responses. COX-1 inhibition by SC 560 (purple, n ϭ 12 arterioles from 9 rats) did not alter the vascular response in contrast to the selective inhibition of COX-2 by NS 398 (red, n ϭ 10 arterioles from 8 rats). Antagonism of EP2, EP4, and IP receptors respectively by AH 6809 (orange, n ϭ 14 arterioles from 13 rats), L 161-982 (green, n ϭ 11 arterioles from 6 rats) and CAY 10441 (blue, n ϭ 12 arterioles from 7 rats) reduced the vascular responses. Blockade of action potentials by TTX (brown, n ϭ 8 arterioles from 3 rats) dramatically reduced the vascular responses. B, Representative example showing infrared images of a preconstricted diving arteriole that reversibly dilated to NMDA application. Pial surface is upward. Scale bar, 20 m. White dashed vertical lines indicate the initial position of the vessel wall. C, D, Effects of COX-1/2 inhibition, EP2, EP4, and IP receptor antagonism, and action potentials blockade on maximal amplitude (C) and magnitude (D) of NMDA-induced vasodilations. Dots represent individual arteriolar responses. Bars and error bars correspond to the mean Ϯ SEM. *, **, and *** statistically different from Ctrl condition with p Ͻ 0.05, 0.01 and 0.001, respectively; n.s., not statistically significant.
Statistical significance of light-induced CBF responses before and after NS 398 application was determined using a paired t test. Drug effects on CBF (at the maximum dose and time efficacy determined in preliminary experiments), LFP, blood gases, blood pressure measurements, and prostaglandin analysis were compared by repeated-measures ANOVA, followed by a post hoc Newman-Keuls test between each condition. When normality of distribution was not met, the Friedman test was used.
Results

COX-2-derived prostaglandins mediate NMDA-induced vasodilations
To identify the prostaglandins involved in NVC, we focused on NMDA receptors for the following reasons: (1) their activation promotes in vivo the release of the vasodilatory PgE 2 and PgI 2 (Lazarewicz and Saliń ska, 1995; Pepicelli et al., 2005) . (2) Similar to COX-2, their activity accounts for approximately one-half of the NVC responses to various sensory stimuli (Niwa et al., 2000; Norup and Lauritzen, 2001; Bakalova et al., 2002; Gsell et al., 2006; Stefanovic et al., 2006; Lecrux et al., 2011) . (3) NMDA receptors blockade occludes the reduction of the NVC responses induced by COX-2 inhibition (Lecrux et al., 2011) , suggesting that most of the NVC response evoked by NMDA receptors is due to the release and action of vasodilatory prostaglandins. Finally, (4) NMDA has been shown to dilate cortical arterioles in acute cortical slices (Fergus and Lee, 1997; Lovick et al., 1999) .
Because the brain slice preparation offers a well controlled extracellular environment suitable for pharmacological manipulations (Iadecola and Nedergaard, 2007) and prostaglandin measurement (Gordon et al., 2008) , we first sought to determine whether vasodilatory prostaglandins could mediate the NMDA-induced vasodilations in young rats. We chose this approach as a good compromise for preservation of slice quality, easily achieved in young animals and essential to preserve neurovascular physiology, and a phenotype of the neuro-glio-vascular unit close to adulthood . Indeed, COX-2 expression (Yamagata et al., 1993; Kaufmann et al., 1996; Tocco et al., 1997) , astrocyte phenotype (Stichel et al., 1991; Houades et al., 2008) and vascular patterns (Harb et al., 2013; Whiteus et al., 2013; Lacoste et al., 2014) maturate during the end of the third postnatal week.
We used 30 M NMDA, a submaximal concentration eliciting large vasodilations (Fergus and Lee, 1997) compatible with their pharmacological investigations . Bath application of NMDA, dilated preconstricted cortical arterioles (maximal dilation 84.7 Ϯ 11.9%, magnitude 47.7 Ϯ 7.6 10 3 % ⅐ s; Fig. 1 ; Table 1 ; Movie 1). Inamajorityofarterioles(nϭ10of16),NMDAdidnotfullybringback luminal diameters to their preconstriction value (83.2 Ϯ 3.5%). How- Figure 2 . Vasodilatory prostaglandins release dynamics induced by NMDA. Dynamics of PgE 2 (A) and 6-keto PgF 1␣ (B) levels in the supernatants (left) and in the slices after treatments (right). Samples were collected before adding COX inhibitors (t ϭ Ϫ30), before (t ϭ 0 min) and during (t ϭ 2 and 5 min) NMDA (30 M; black bar and vertical gray zone), and after removing NMDA (t ϭ 10, 20 and 30 min). PgE 2 (A) and to a lesser extent and 6-keto PgF 1␣ (B) levels increased during NMDA application (NMDA, black traces) but not after NMDA removal. No change was observed when applying NMDA vehicle (water, Ctrl, gray traces) or when NMDA was applied in presence of NS 398 (red traces) or SC 560 (purple traces). Tissue content (right) in PgE 2 (A) and 6-keto PgF 1␣ (B) were elevated when slices were treated with NMDA in absence of COX inhibitor. Numbers in parenthesis represent the number of replicates. Error bars are SEM. ever in some cases (n ϭ 6 of 16) it further dilated arterioles by 12.0 Ϯ 3.5%.
To evaluate whether the biosynthesis of vasodilatory prostaglandins was involved, slices were pretreated with the nonselective COXs inhibitor indomethacin at 5 M (Table 3) . This treatment abolished almost completely the NMDA responses (maximal dilation: 25.0 Ϯ 5.0%, p ϭ 0.002412, U (16,6) ϭ 9, Mann-Whitney U test; magnitude: 2.9 Ϯ 5.0 10 3 % ⅐ s, p ϭ 0.000804, U (16,6) ϭ 6, Mann-Whitney U test; Fig. 1 ) indicating that vasodilatory prostaglandins are recruited during NMDAinduced vasodilations. We next determined the relative contribution of COX-1 and COX-2 to these responses. Selective COX-1 inhibition with SC 560 (100 nM; Fig. 1A ), suggesting that COX-1-derived prostaglandins may participate in the initial phase of the NVC response.
In contrast with SC 560, and similarly to indomethacin, selective COX-2 inhibition with NS 398 (10 M; Table 3 ) dramatically reduced the maximal amplitude (29.3 Ϯ 5.3%, p ϭ 0.000555, U (16,10) ϭ 18, Mann-Whitney U test; Fig. 1 ) and magnitude of the response (10.1 Ϯ 3.8 10 3 % ⅐ s, p ϭ 0.000910, U (16,10) ϭ 20, Mann-Whitney U test; Fig. 1 ). NS 398 strongly diminished the maximal response during the 5 min of NMDA application (14.1 Ϯ 4.1%, p ϭ 0.000025, U (16,10) ϭ 0, Mann-Whitney U test; Fig. 1A ). Similarly to the in vivo context (Niwa et al., 2000 (Niwa et al., , 2001 Bakalova et al., 2002; Stefanovic et al., 2006; Lecrux et al., 2011) our observations demonstrate a prominent role of COX-2 metabolites in NVC validating therefore this ex vivo approach. We also report that the initial phase of the NVC response to NMDA is sensitive to SC 560 and NS 398.
To identify the nature of the dilatory prostaglandins involved, we antagonized the vasodilatory PgE 2 and PgI 2 receptors. Since there is no commercially available selective EP2 antagonist, we used the EP2/ EP1 antagonist AH 6809 (10 M; Table 3 ). AH 6809 strongly reduced the maximal amplitude (35.8 Ϯ 7.2%, p ϭ 0.002069, U (16, 14) ϭ 40, Mann-Whitney U test; Fig. 1 ) and the magnitude of NMDA-induced vasodilations (16.7 Ϯ 4.9 10 3 % ⅐ s, p ϭ 0.003321, U (16, 14) ϭ 43, Mann-Whitney U test; Fig. 1 ). We next thought to block EP4 receptors with its selective antagonist L 161-982 (1 M; Table 3 ). L 161-982 significantly impaired the maximal amplitude (43.8 Ϯ 11.9%, p ϭ 0.019827, U (16,11) ϭ 41, Mann-Whitney U test; Fig. 1 Fig. 1 ). The reduction of NMDA-induced vasodilations by EP2, EP4, and IP receptor antagonists and during COX-2 or COX-1 inhibition suggests that PgE 2 and PgI 2 essentially derived from COX-2 activity underlie these vascular responses. The evoked response was not altered by vehicle (gray line), whereas the EP1/EP2 receptor antagonist AH 6809 (orange, n ϭ 6 rats) and EP4 receptor antagonist L 161-982 (green, n ϭ 4 rats), but not the IP receptor antagonist CAY 10441 (blue, n ϭ 5 rats), decreased this response. The SEM envelopes the mean traces. B, C, Maximal whisker-evoked changes in CBF (B) and in LFPs (C), under baseline (CBF: 8.0 Ϯ 1.1%, 10.9 Ϯ 1.3%, and 8.6 Ϯ 1.2%; LFPs: 100.0 Ϯ 16.7%, 100.0 Ϯ 27.0%, and 100.0 Ϯ 20.8%) and vehicle (CBF: 8.7 Ϯ 1.0%, 11.9 Ϯ 1.2% and 9.0 Ϯ 1.5%; LFPs: 122.3 Ϯ 30.8%, 105.0 Ϯ 14.6%, and 115.4 Ϯ 31.3%) conditions and application of AH 6809 (CBF: 5.9 Ϯ 1.3%; LFPs: 126.6 Ϯ 30.8, n ϭ 6 and 4 rats, respectively), L 161-982 (CBF: 8.7 Ϯ 2.1%; LFPs: 101.9 Ϯ 17.0%, n ϭ 4 rats) or CAY 10441 (CBF: 7.9 Ϯ 1.1%; LFPs: 135.0 Ϯ 38.4%, n ϭ 5 and 3 rats, respectively). Whisker stimulation induced increases in the amplitude of the LFPs in the contralateral barrel cortex as shown by the representative tracings (average of 7 trials from 1 rat) for each compound (C, top). Contralateral LFP amplitudes were normalized by the mean amplitude under baseline conditions. *p Ͻ 0.05 and **p Ͻ 0.01 compared with vehicle conditions, ૺp Ͻ 0.05 compared with Ctrl conditions, n.s., not statistically significant. Dots represent individual responses. Horizontal bars and error bars represent mean Ϯ SEM. 
NMDA promotes the biosynthesis and release of PgE 2 and PgI 2 in cortical slices
To confirm that PgE 2 and PgI 2 are indeed produced and released by NMDA applications we sought to measure the content in PgE 2 and 6-keto prostaglandin F 1 ␣ (6-keto PgF 1␣ ), the stable metabolite of PgI 2 , produced in slices before, during and after NMDA application in presence or absence of COX inhibitors (Fig. 2) . Prostaglandins and thromboxane were measured by LC-ESI-MS/MS which permits an unambiguous identification of prostaglandins (Schmidt et al., 2005 (Schmidt et al., , 2014 . Because the amount of PgE 2 that can be released by slices is very low (Gordon et al., 2008) , four slices were coincubated each time. Prostaglandin analysis was performed in the supernatant at different time points and in the tissue at the end of the treatments (Fig. 2) . The temporal profile of PgE 2 content ( Fig. 2A) was significantly altered when slices were treated by NMDA ( p ϭ 0.00514, Q (7,3) ϭ 20.21, Firedman test), but not when NMDA was omitted ( p ϭ 0.09697, Q (7,3) ϭ 12.11, Firedman test) or when NMDA was applied in presence of NS 398 ( p ϭ 0.19886, Q (7,3) ϭ 9.82, Firedman test) or SC 560 ( p ϭ 0.19417, Q (7,2) ϭ 9,90, Firedman test). Similarly to PgE 2 , the temporal profile of 6-keto PgF 1␣ (Fig.  2B ) was modified by NMDA treatment ( p ϭ 0.03266, Q (7,3) ϭ 15.27 with NMDA and p ϭ 0.24846, Q (7,3) ϭ 9,06 without NMDA, Firedman tests) but not in presence of NS 398 ( p ϭ 0.34416, Q (7,3) ϭ 7.87, Firedman test) or SC 560 ( p ϭ 0.49799, Q (7,2) ϭ 6,36, Firedman test). PgE 2 content in the supernatant reached a maximum of 54 Ϯ 28 pg/ml) 5 min after the application of NMDA ( Fig. 2A) and remained elevated in the tissue after NMDA treatment without COX inhibitor (32 Ϯ 22 pg/4 slices). Although in the supernatant the content in 6-keto PgF 1␣ was often below the lower limit of quantification (see Materials and Methods), during NMDA application a maximal level of 6-keto PgF 1 ␣ (9 Ϯ 8 pg/ml) could be reached after 5 min and was reliably quantifiable in the tissue after NMDA treatment without COX inhibitor (23 Ϯ 13 pg/4 slices; Fig. 2B ).
Similarly to previous in vivo observations (Lazarewicz and Saliń ska, 1995; Pepicelli et al., 2005; Anrather et al., 2011) , our ex vivo data confirm that NMDA promotes the release of PgE 2 and, to a lesser extent, of 6-keto PgF 1␣ , dependent on COX-1 and COX-2 activity, hence supporting the recruitment of the PgE 2 and PgI 2 vasodilatory receptors in NMDA-induced vasodilations.
The NVC response to sensory stimulation recruits PgE 2 vasodilatory receptors Our ex vivo data have indicated that NMDA-induced vasodilations are mediated by the release of PgE 2 and PgI 2 chiefly derived form COX-2 activity and activation of EP2, EP4, and IP receptors. Because NVC responses to sensory stimulations also involve NMDA receptors and COX-2 metabolites (Niwa et al., 2000; Norup and Lauritzen, 2001; Bakalova et al., 2002; Gsell et al., 2006; Stefanovic et al., 2006; Lecrux et al., 2011) we sought to determine whether EP2, EP4, and IP receptors were involved in the NVC response to sensory stimulation and in adult animals.
It has been recently estimated that in vivo the majority of the CBF increase in response to sensory stimulation is mediated by capillaries dilation (Hall et al., 2014) . We used LDF to obtain a global readout of CBF changes including layer IV of the somatosensory cortex which exhibits the highest neuronal and capillary density (Woolsey et al., 1996; Tsai et al., 2009 ) and where the NVC response initiates and propagates to upstream diving arterioles (Silva and Koretsky, 2002; Tian et al., 2010; Hall et al., 2014; Filosa et al., 2015) . Indeed, with appropriate laser wavelength, fiber diameter and source-detector separation (see Materials and Methods) it has been estimated that LDF samples ϳ1 mm 3 of tissue at a depth down to 680 m (Fredriksson et al., 2009 ). PgE 2 and PgI 2 receptor antagonists were delivered by a single intracisternal injection. Although this strategy has proven efficient with little or no side effect on physiological parameters (Lecrux et al., 2011 (Lecrux et al., , 2012 , the precise concentration in the parenchyma is unknown as it is governed by diffusion and largely depends on tissue depth. We therefore tested different antagonist concentrations (Table 4) . To avoid unspecific effects of the antagonists or their vehicle (Matsuura et al., 2009 ) at high concentrations, we did not inject drugs beyond 10 Ϫ4 M . The EP2/EP1 antagonist AH 6809 was most effective at inhibiting the NVC response when delivered at 1 M (Table 4) . Surprisingly, at higher concentrations the AH 6809-mediated inhibition of the NVC response was lower (Table 4 ). This dosedependent effect may be due to the lower affinity of AH 6809 for the EP1 receptor than for the EP2 receptor (Table 3 ). The combined antagonism of EP1/EP2 receptors obtained at higher doses may have unmasked the vasoconstrictory effect of EP1 receptors (Dabertrand et al., 2013) resulting in an apparent lower inhibition of the NVC response. Consistent with the results in acute slices, AH 6809 (1 M), reduced the NVC responses to whisker stimulation ( p ϭ 0.0069, F (2,10) ϭ 8.54, repeated-measures ANOVA; Fig. 3 A, B) , without altering the whisker-evoked neuronal activity measured by the amplitude of the LFPs ( p ϭ 0.1453, F (2,6) ϭ 2.707, repeated-measures ANOVA; Fig. 3C ), blood gases or blood pressure (Table 5) . Similarly L 161-982 (100 M; Table 4 ) significantly reduced the hemodynamic response ( p ϭ 0.0112, F (2,6) ϭ 10.43, repeated-measures ANOVA; Fig.  3 A, B ) without altering LFPs ( p ϭ 0.8856, F (2,6) ϭ 0.1240, repeated-measures ANOVA; Fig. 3C ) or physiological parameters (Table 5 ). In contrast with ex vivo observations, IP receptor blockade with CAY 10441, even when delivered at high concentrations (100 M; Table 4), had no or virtually no effect on the evoked NVC ( p ϭ 0.4560, F (2,8) ϭ 0.87, repeated-measures ANOVA; Fig. 3 A, B) and electrophysiological ( p ϭ 0.1412, F (2,4) ϭ 3.323, repeated-measures ANOVA; Fig. 3C ) responses, or physiological parameters (Table 5 ). In line with our ex vivo data on vascular reactivity (Fig. 1 ) and prostaglandin analysis (Fig. 2) , these in vivo observations indicate that COX-2-derived PgE 2 acting on EP2 and EP4 receptors is the main vasodilatory prostaglandin involved in NVC responses to sensory stimulations.
Pyramidal cells are the main cell type constitutively expressing COX-2
To identify the cellular sources of PgE 2 in NVC, we next examined the cellular distribution of COX-2 in the different cellular elements of the neuro-glio-vascular unit. Although the NVC response initiates in layer IV of the somatosensory cortex (Silva and Koretsky, 2002; Figure 5 . Sensitivity of RT-mPCR protocols. Total cortical RNAs (500 pg) were subjected to RT-PCR protocols designed for the molecular characterization of perivascular astrocytes (A) and cortical neurons (B). The PCR products were resolved in separate lanes by agarose gel electrophoresis in parallel with ⌽x174 digested by HaeIII as molecular weight marker and stained with ethidium bromide. The amplified fragments corresponding to astrocytic (A, left) and neuronal (B, top) molecular markers, as well as PgE 2 and PgI 2 synthesizing enzymes (A, right, B, bottom) had the size predicted by their mRNA sequence (Table 2) . Tian et al., 2010; Filosa et al., 2015) we focused on layers I-IV in which COX-2 cells predominates across the different cortical areas (Breder et al., 1995) . Consistently, COX-2 immunolabeling obtained from 7 different rats was particularly abundant in layer II-III (Fig. 4) . It mainly consisted in cytoplasmic staining and was virtually absent from the vascular bed stained with LEA (Fig. 4A) or from microglia immunostained for Iba-1 (Fig. 4B) . Similarly, very few S100␤-immunolabeled astrocytes were COX-2-immunopositive (2.1 Ϯ 0.9%, n ϭ 3199 S100␤-positive cells from 4 rats; Fig. 4C ). In contrast, most COX-2-immunoreactive cells displayed a nucleus positive for Satb2 (Fig. 4D) , a transcription factor of pyramidal cells (S. Lee et al., 2010) . COX-2 cells accounted for 27.7 Ϯ 2.6% of Satb2 neurons (n ϭ 6175 Satb2-positive cells from 4 rats). This suggests that pyramidal neurons, over astrocytes, microglia, and endothelial cells, are the primary cell type constitutively expressing COX-2. Nonetheless it remains unclear whether COX-2-derived vasodilatory prostaglandins are directly produced by pyramidal neurons or if their synthesis is transcellular, as suggested for 20-hydroxyeicosatetraenoic acid (Mulligan and MacVicar, 2004; , another arachidonic acid derivative.
Astrocytes have the capability to produce PgE 2 essentially derived from COX-1 activity To determine the capacity of astrocytes and neurons to produce PgE 2 and PgI 2 from arachidonic acid we assessed at the single-cell level the cellular distribution of PgE 2 and PgI 2 synthesizing enzymes including the rate limiting and the terminal synthesizing enzymes in young rats. Two scRT-PCR protocols were respectively designed for astrocyte and neuron characterizations. The efficiency of the protocols was tested on 500 pg of total RNA purified . In response to just-above-threshold current pulse, this neuron fired action potentials with a long lasting biphasic AHP and little frequency adaptation (middle trace). Near saturation, it showed the typical firing of a regular spiking neuron with marked 4 frequency adaptation and spike amplitude accommodation (upper trace). E, The pyramidal cell shown in D expressed vGluT1, CCK, COX-1, COX-2, and cPGES. F, Voltage responses induced by injection of current pulses in a fusiform interneuron (bottom traces). Inset, IR-DGC image of the recorded interneuron, pial surface is upward (scale bar, 10 m). Note the high input resistance of the cell observed at hyperpolarizing current pulses (middle traces). In response to just-above-threshold current pulse, this interneuron fired a first action potential with a monophasic AHP followed by action potentials with complex AHP. Near saturation, this neuron showed the firing of an adapting-VIP interneuron with marked frequency adaptation and spike amplitude accommodation (upper trace). G, This interneuron expressed vGluT1, GAD65, GAD67, CR, VIP, CCK, COX-2, and cPGES. from rat cerebral cortex. Figure 5 shows that for each protocol the sizes of all PCR-generated fragments were as predicted by the mRNA sequences (Table 2 ) and confirms the sensitivity of the scRT-PCR procedures .
To facilitate astrocytes identification, slices were vitally stained with SR101 (n ϭ 35 cells) or TxRed (n ϭ 9 cells), two related fluorescent dyes of cortical astrocytes (Nimmerjahn et al., 2004) . Labeled cells were selected in the vicinity of an arteriole (Fig. 6A) and at the border of layers I and II which contain a high density of astrocytes (McCaslin et al., 2011) and the highest astrocytic molecular diversity (Zeisel et al., 2015) . Cells were also selected according to the presence of a prominent perivascular process (Fig. 6A) or a cell body directly apposed to an arteriole (n ϭ 6 cells). In line with their glial identity , labeled cells exhibited small somata ( Fig. 6A ; Table 6 ). Whole-cell recordings revealed a linear I/V curve (Fig. 6B) , a hyperpolarized membrane potential (Ϫ87.9 Ϯ 1.3 mV), a low input resistance (46.7 Ϯ 7.7 M⍀) and an inability to generate action potentials, which are all characteristics of mature cortical astrocytes Houades et al., 2008) . The molecular analysis of these cells revealed the expression of at least one of the two astrocytic markers; GFAP and S100␤ (Fig. 6C ). Consistent with a low level of GFAP in quiescent cortical astrocytes (Wilhelmsson et al., 2006; Houades et al., 2008) , GFAP was detected in one-half of the astrocytes, whereas S100␤ was expressed in most astrocytes (98%, n ϭ 43 of 44 cells).
As previously observed (Takano et al., 2006; Lecrux et al., 2011) , COX-1 was detected in a subpopulation of perivascular astrocytes (20%, n ϭ 9 of 44 cells; Figs. 6C,7) . In agreement with our immunohistochemical observations (Fig. 4C) , a minority of S100␤-positive astrocytes expressed COX-2 (5%, n ϭ 2 of 44 cells; Fig. 7) . The PGES isoform, mPGES1, was never observed (Figs. 6C, 7B) . In contrast, mPGES2 and cPGES were respectively detected in 5% (n ϭ 2) and 32% (n ϭ 14) of the astrocytes (Figs.  6C, 7B ). PGIS was detected in 8 cells (18%; Fig. 7 A, C) and was systematically coexpressed with cPGES. Interestingly expression of cPGES (89%, n ϭ 8 of 9 cells, p ϭ 0.0001, Fisher's exact test) and PGIS (44%, n ϭ 4 of 9 cells, p ϭ 0.0422, Fisher's exact test) was enriched in COX-1-positive astrocytes. These data confirm the ability of perivascular astrocytes to synthesize COX-1-derived PgE 2 (Takano et al., 2006; Gordon et al., 2008) and PgI 2 to a lesser extent.
Pyramidal cells are the main cell type equipped for COX-2-derived PgE 2 biosynthesis
We next characterized layer II-III neurons to confirm at the mRNA level our immunohistochemical observations (Fig. 4D) and further determine the expression profile of PgE 2 and PgI 2 synthesizing enzymes. Pyramidal cells were chosen on the basis of a prominent apical dendrite extending from a large triangular soma (n ϭ 24 cells; Fig. 6D , inset; Table 6 ). In contrast, collected interneurons (n ϭ 66 cells) displayed a round (n ϭ 4 cells), ovoid (n ϭ 16 cells), or fusiform soma (n ϭ 46 cells; Fig. 6F, inset) . Whole-cell current-clamp recordings revealed a resting membrane potential more hyperpolarized in pyramidal cells than in interneurons (Fig. 6 D, F ; Table 7 ). Pyramidal cells fired larger and wider action potentials than interneurons (Fig. 6 D, F ; Table  8 ). They also discharged at a lower-frequency (Fig. 6 D, F ; Table  9 ). This confirms the regular spiking phenotype of pyramidal cells (McCormick et al., 1985; Cauli et al., 2000; Andjelic et al., 2009; Karagiannis et al., 2009) . Consistently, the molecular analysis of pyramidal cells revealed expression of the vesicular glutamate transporter, vGluT1 (Fig. 6E) but none of the two GABA synthesizing enzymes. CCK (Fig. 6E ) and, to a lesser extent, CB but not the other interneuron markers (Table 10) , were frequently observed in pyramidal cells Andjelic et al., 2009; Karagiannis et al., 2009) . In contrast, interneurons expressed at least one of the two GADs and frequently the interneuron markers ( Fig. 6G; Table 10 ), particularly CR, NPY, or VIP. These electrophysiological and molecular data confirm the glutamatergic and the GABAergic phenotypes of pyramidal cells and interneurons, respectively.
COX-1 was observed in 38% (n ϭ 9 of 24; Fig. 6E ) and 27% (n ϭ 18 of 66) of pyramidal cells and interneurons, respectively, and COX-2 in 33% of pyramidal cells (n ϭ 8 of 24 cells; Figs. 6E, 7 A, C) but only in 8% of interneurons (n ϭ 5 of 66 cells; Figs. 6G, 7 A, C). Coexpression of both COX isoforms occurred in 17% of pyramidal cells (Fig. 6E ) and in 5% of interneurons. Similar to astrocytes, mPGES1 was never detected in neurons (Figs. 6 E, G,  7B) . In contradistinction, mPGES2 and cPGES were respectively detected in 29 (n ϭ 7 of 24 cells) and 75% (n ϭ 18 of 24 cells; Figs. 6E, 7B) of pyramidal cells and in 26 (n ϭ 17 of 66 cells) and 53% (n ϭ 35 of 66 cells) of interneurons (Figs. 6G, 7B) . Interestingly, expression of at least one terminal PgE 2 synthesizing enzyme was observed in all COX-1-or COX-2-positive pyramidal cells (Figs. 6E, 7C) , and in a majority of interneurons positive for COX-1 (94%, n ϭ 17 of 18 cells) or COX-2 (80%, n ϭ 4 of 5 cells; Figs. 6G, 7C). PGIS was expressed in 25% of pyramidal cells (n ϭ 6 of 24 cells, Fig. 7 A, C) and only in 11% of interneurons (n ϭ 7 of 66 cells; Fig. 7 A, C) . These data indicate that subpopulations of cortical neurons can synthesize PgE 2 and, to a lesser extent, PgI 2 .
The occurrence of COX-1 was similar in astrocytes, pyramidal cells, and interneurons (astrocytes vs pyramidal cells, p ϭ 0.1563, astrocytes vs interneurons, p ϭ 0.5006; pyramidal cells vs interneurons, p ϭ 0.4364, Fisher's exact tests; Fig. 7 A, C) . In con- Table 6 . Somatic properties of different cortical cells trast, our immunocytochemical (Fig. 4D ) and scRT-PCR data showed that pyramidal neurons were the main cell type constitutively expressing COX-2 (astrocytes vs pyramidal cells, p ϭ 0.0026, astrocytes vs interneurons, p ϭ 0.7000; pyramidal cells vs interneurons, p ϭ 0.0046; Fisher's exact tests; Fig. 7 A, C) . Expression of at least one PGES was more frequent in neurons than in astrocytes (astrocytes vs pyramidal cells, p ϭ 0.0001; astrocytes vs interneurons, p ϭ 0.0018; pyramidal cells vs interneurons, p ϭ 0.1221; Fisher's exact tests; Fig. 7 A, C) . cPGES was the main isoform in the three cell types and was most frequent in neurons and, particularly, in pyramidal cells (astrocytes vs pyramidal cells, p ϭ 0.0009; astrocytes vs interneurons, p ϭ 0.0327; pyramidal cells vs interneurons, p ϭ 0.0894; Fisher's exact tests; Fig. 7B ). Expression mPGES2 was infrequent in neurons and very rare in astrocytes (astrocytes vs pyramidal cells, p ϭ 0.0073; astrocytes vs interneurons, p ϭ 0.0041; pyramidal cells vs interneurons, p ϭ 0.7904; Fisher's exact tests; Fig. 7B ). PGIS was similarly rare in neurons and astrocytes (astrocytes vs pyramidal cells, p ϭ 0.5415; astrocytes vs interneurons, p ϭ 0.2717; pyramidal cells vs interneurons, p ϭ 0.1000; Fisher's exact tests; Fig. 7 A, C) . Consistent with prostaglandin analysis (Fig. 2) , these data indicate that perivascular astrocytes and cortical neurons are better equipped to produce PgE 2 than PgI 2 . They also suggest that pyramidal neurons are the main source of PgE 2 -derived from COX-2 activity. Consistent with a neuronal origin of PgE 2 in NVC, NMDAinduced vasodilations were dramatically reduced by blockade of action potentials with TTX (5 M, n ϭ 8 arterioles, maximal dilation 20.8 Ϯ 3.9%, p ϭ 0.00002, U (16, 8) ϭ 3, magnitude 9.0 Ϯ 2.2 10 3 .%.s, p ϭ 0.00037, U(16,8) ϭ 10; Mann-Whitney U tests; Fig. 1 ) indicating that neuronal activity is required for these responses.
Optogenetic stimulation of pyramidal cells induces COX-2-dependent hyperemic responses
Similar to LDF, it has been reported that 95% of the laser-speckle contrast imaging signal comes from the top 700 m of tissue (Davis et al., 2014) . To evaluate functionally the capability of pyramidal cells to release vasodilatory prostaglandins in vivo, we combined direct optogenetic stimulation of channelrhodopsin-2 (ChR-2)-expressing neurons with laser speckle contrast imaging of cerebral blood flow (Scott and Murphy, 2012) . Similarly to rats, mice exhibit a COX-2-dependent NVC response to sensory stimulation (Niwa et al., 2000; Bakalova et al., 2002; Stefanovic et al., 2006; Lecrux et al., 2011) . We therefore took advantage of available Cre driver lines to obtain an expression of ChR2 in pyramidal cells. Efficient expression of ChR-2 was obtained by crossing Emx1-Cre mice with Ai32 mice which permits a conditional expression of ChR2 and a robust photoexcitability of pyramidal cells (Madisen et al., 2012) . Photoexcitation at 473 nm (100 Hz, 5 ms, 3 mW) of Emx1-Cre;Ai32 mice (n ϭ 5 mice) Figure 7 . Expression profiles of the PgE 2 and PgI 2 synthesizing enzymes. A, Histograms depicting the occurrence of prostanoid synthesizing enzymes in identified cell types. PGES denotes expression of mPGES1, 2, and/or cPGES. Layer II-III cortical pyramidal neurons (n ϭ 24 cells, black) express much more frequently COX-2, than perivascular astrocytes (n ϭ 44 cells, red) and interneurons (n ϭ 66 cells, white). B, Occurrence of the three PGES isoforms in identified cell types. mPGES1 is not detected in any cell types. mPGES2 is more frequently observed in pyramidal neurons and interneurons than in astrocytes. cPGES is detected in the three cell types but more frequently in pyramidal cells than in astrocytes. *, **, and *** statistically significant with p Ͻ 0.05, p Ͻ0.01, and p Ͻ0.001 respectively. C, Coexpression of prostanoid synthesizing enzymes in identified cell types. The occurrence of cells positive for an enzyme is proportional to the size of the box in a given cell type. Coexpression of PGES (green) and PGIS (blue) with COX-1 (top, purple) and with COX-2 (bottom, red) in astrocytes (S100␤ and/or GFAP-positive; left), pyramidal cells (vGluT1-positive; middle) and interneurons (GAD65-and/or 67-positive; right). elicited a rapid and transient increase in cerebral blood flow ( Fig.  8 ; magnitude 118.3 Ϯ 24.2%.s, maximal change 27.7 Ϯ 3.5%) that was not observed with Thy1-YFP mice that do not express ChR2 (n ϭ 4 mice, magnitude 2.9 Ϯ 3.2%.s, p ϭ 0.01587, U (5,4) ϭ 0; maximal change 5.6 Ϯ 1.2%, p ϭ 0.01587, U (5,4) ϭ 0, MannWhitney U tests; Fig. 8B-D) . Consistent with the release of COX-2-derived PgE 2, laser speckle contrast changes evoked by photoexcitation of Emx1-Cre;Ai32 pyramidal cells were reduced by application of the COX-2 inhibitor NS 398 (100 M, Magnitude 55.9 Ϯ 12.4%.s, p ϭ 0.0226, t (4) ϭ 3.6064, paired t test, maximal change 16.0 Ϯ 3.7%, p ϭ 0.0226, t (4) ϭ 3.6080, paired t test; Fig. 8B-D) . These optogenetic results show that direct activation of pyramidal cells is sufficient to release COX-2-derived vasodilatory prostaglandins. 
Discussion
Here we deciphered the molecular and cellular mechanisms responsible for the biosynthesis and activity of vasodilatory prostaglandins involved in NVC (Fig. 9) . We identified in slices the rate-limiting enzyme involved in this pathway by showing that COX-2, but also to a lesser extent COX-1, metabolites mediate NMDA-induced vasodilations. Further, we identified PgE 2 as the main vasodilatory prostaglandins by demonstrating ex vivo and in vivo the implication of its EP2 and EP4 receptors and by showing its release ex vivo using LC-ESI-MS/MS. We found that pyramidal cells are the main cell type equipped for PgE 2 synthesis derived from COX-2 activity. Moreover we showed that increased activity of these neurons through direct optogenetic stimulation evoked COX-2-dependent NVC responses, hence demonstrating a key role for PgE 2 -derived from pyramidal cells in NVC responses.
Cellular distribution of PgE 2 and PgI 2 synthesizing enzymes
Our data showing COX-1 expression in various cell types are supported by previous observations demonstrating its localization in microglia, astrocytes, neurons and endothelial cells (Takano et al., 2006; Cahoy et al., 2008; Gordon et al., 2008; Tang and Vanhoutte, 2008; Tanaka et al., 2009; Anrather et al., 2011; Lecrux et al., 2011) . In contrast, we observed by immunohistochemistry and scRT-PCR that COX-2 is largely restricted to pyramidal neurons, rarely in astrocytes and interneurons, and virtually absent in microglial cells and the vascular bed (Yamagata et al., 1993; Breder et al., 1995; Kaufmann et al., 1996; Wang et al., 2005; Takano et al., 2006; Cahoy et al., 2008; Gordon et al., 2008; Anrather et al., 2011; Lecrux et al., 2011 Cahoy et al., 2008) , whereas mPGES1 was virtually absent from neurons and astrocytes (Ikeda-Matsuo et al., 2006; Cahoy et al., 2008) . We also confirmed a rather infrequent PGIS expression (Mehl et al., 1999; Cahoy et al., 2008) . Importantly, we disclosed that COX-2-positive pyramidal cells systematically express a cPGES and/or mPGES2 to a lesser extent. This indicates that under homeostatic conditions COX-2-derived PgE 2 is essentially produced by pyramidal cells.
Origins of vasodilatory prostaglandins in NVC
Perivascular astrocytes can release COX-1-, but not COX-2-derived, vasodilatory prostaglandins following activation of group I metabotropic glutamate receptors (Zonta et al., 2003; Takano et al., 2006; Gordon et al., 2008) . However, the recruitment of this pathway during sensory stimulation is unlikely because pharmacological and genetic evidence showed that such stimuli elicit COX-2, but not COX-1,-dependent hyperemic responses (Niwa et al., 2000 (Niwa et al., , 2001 Bakalova et al., 2002; Stefanovic et al., 2006; Lecrux et al., 2011) . Furthermore, the recruitment of astrocytes by group I metabotropic glutamate receptors has been recently questioned (Calcinaghi et al., 2011; Nizar et al., 2013; Sun et al., 2013; Bonder and McCarthy, 2014; Jego et al., 2014) . This suggests that under normal conditions sensory stimulations do not substantially recruit vasodilatory prostaglandins produced by astrocytes.
We found that NMDA-induced vasodilations were almost completely abolished by COX-2 inhibition, suggesting that the NMDA-dependent fraction of the NVC response is essentially mediated by vasodilatory prostaglandins. Our results indicating that COX-2-derived PgE 2 released during sensory stimulation has a pyramidal origin are supported further by optogenetic observations showing that the selective photostimulation of CaMKII␣ pyramidal cells, which extensively coexpress COX-2 (Kaufmann et al., 1996) , evoked a hemodynamic response (J. H. Lee et al., 2010; Ji et al., 2012) . In addition, the NVC responses induced by the photostimulation of pyramidal neurons, but not by sensory stimulation, are virtually insensitive to ionotropic glutamate receptors blockade (Scott and Murphy, 2012) . This further points to release of vasodilatory messengers by pyramidal cells. Since the NVC involves numerous vasoactive messengers Leithner et al., 2010; Liu et al., 2012) , it is likely that the optogenetic photostimulation of pyramidal cells recruits indirectly other vasoactive messengers. Consistently, a substantial fraction of the NVC response to sensory stimulation is insensitive to COX-2 inhibition (Niwa et al., 2000; Bakalova et al., 2002; Stefanovic et al., 2006; Lecrux et al., 2011) and PgE 2 receptor antagonism (present study). Interestingly, COX-2 has been described in dendrites, spines or axon terminals (Kaufmann et al., 1996; Wang et al., 2005) , suggesting that pyramidal cells can remotely release PgE 2 .
We found that the initial phase of NMDA-induced vasodilations was also COX-1-dependent. The cellular origin of COX-1-derived prostaglandins released by NMDA remains undetermined given the large cellular distribution of COX-1 (see above) and the widespread expression of NMDA receptors in various neuronal types , but also in some astrocytes, microglial and endothelial cells (Lalo et al., 2006; Kaindl et al., 2012; LeMaistre et al., 2012 ). Microglia, a major cell type expressing COX-1, can release PgE 2 upon NMDA stimulation, but secondary to neuronal ATP release (Anrather et al., 2011) making unlikely their contribution to the early NVC response. The expression of COX-1 in neurons and astrocytes suggests that these cell types might be responsible for the early NVC response. Finally, given that endothelial cells play a key role in fast hemodynamics , they might also contribute to the early NVC response.
Release of prostaglandins
Consistent with in vivo data (Lazarewicz and Saliń ska, 1995; Pepicelli et al., 2005; Anrather et al., 2011) we observed a COX-1 and COX-2-dependent release of PgE 2 and 6-keto PgF 1␣ . The level of PgE 2 release by NMDA is approximately one-half that found with mGluR1/5 agonists (Gordon et al., 2008) , suggesting that they are more efficient than NMDA at inducing PgE 2 release. This is consistent with widespread expression of mGluR1/5 in astrocytes and neurons (Porter and McCarthy, 1996; Cauli et al., 2000) . However, number of slices and duration of incubation were not described (Gordon et al., 2008 ) making a direct comparison difficult. Furthermore, due to cross-reactivity among the different prostaglandins, the content in PgE 2 may have been overestimated by using immunoassay (Schmidt et al., 2005) . Interestingly, in line with in vivo observations (Lazarewicz et al., 2000) , using LC-ESI-MS/MS we found that up to 396 Ϯ 141 pg/ml PgD 2 was released by NMDA, a prostaglandin structurally similar to PgE 2 .
The dynamics of the NMDA-dependent PgE 2 and 6-keto PgF 1␣ (Fig. 2 ) are overall compatible with the kinetics NMDAinduced vasodilations (Fig. 1) . However a direct comparison is difficult given the different mode of NMDA delivery and washout between supernatant analysis and vascular reactivity (Mishra et Figure 9 . Biosynthesis and vasodilatory effects of PgE 2 and PgI 2 . Increased intracellular calcium activates phospholipase A2 (PLA 2 ). Arachidonic acid (AA) is released from membrane phospholipids (MPL) by PLA 2 and metabolized by COX-1 or COX-2 to produce the intermediary prostaglandin H 2 (PgH 2 ). PgE 2 and PgI 2 are, respectively, synthesized from PgH 2 by PGES and PGIS. Upon binding and action on type 2 or 4 PgE 2 (EP2/4) or PgI 2 (IP) receptors these two prostaglandins relax smooth muscle cells (SMCs) or pericytes and dilate blood vessels. AA can be also metabolized by a cytochrome P450-epoxygenase (Cyp450) to produce 14,15-epoxyeicosatrienoic acid (14,15 EET) which induces EP2-dependent vasodilation. EC, Endothelial cell. SC 560 and NS 398 are selective COX-1 and COX-2 inhibitors respectively. Indomethacin (Indo) is a nonselective COX-1/2 inhibitor. AH 6809, L161-982, and CAY 10441 are EP2, EP4, and IP antagonists, respectively. al., 2014). The sustained vasodilation after NMDA washout is reminiscent of an intracellular Ca 2ϩ increase after a prolonged exposure of NMDA, involving an initial increase via NMDA receptors followed by a secondary activation of other Ca 2ϩ -permeable channels including transient receptor potential channels (Olah et al., 2009 ) and/or voltage-gated Ca 2ϩ channels (Oda et al., 2014) . Recruitment of extrasynaptic NMDA receptors are likely to be responsible for this secondary Ca 2ϩ increase (Oda et al., 2014) and overproduction of PgE 2 (Stark and Bazan, 2011). Whether or not these different initial entry points are specifically coupled with COX-1 and/or COX-2 remains to be determined.
Prostaglandin receptors in NVC
The prostaglandin receptors EP2, EP4, and IP are expressed in cerebrovascular smooth muscle cells and pericytes (Myren et al., 2010 (Myren et al., , 2011 Dabertrand et al., 2013; Hall et al., 2014) . We observed an impairment of the NVC responses by the EP2 and EP4 antagonists both ex vivo and in vivo. These data suggesting an involvement of PgE 2 are consistent with recent observations showing a recruitment of EP4 receptors in cerebral vasodilation evoked by glutamate (Hall et al., 2014) . Antagonism of both EP2 and EP4 receptors reduced the maximal amplitude of NMDAinduced vasodilation, but their magnitude were only impaired by the EP2 antagonist, indicating that EP2 receptors may have a longer lasting vasodilatory effect than EP4 receptors. This is consistent with the reported agonist-induced internalization of EP4 but not EP2 receptor (Desai et al., 2000) . This further suggests that EP2 receptor would be the major vasodilatory PgE 2 receptor activated during a sustained hyperemic response. Because 14,15-EET can induce vasodilation by acting on EP2 receptors (Yang et al., 2010) , the AH 6809-sensitive vasodilation could be also explained by the release of 14,15-EET from astrocytes (Alkayed et al., 1996 (Alkayed et al., , 1997 Fig. 9) . Although the IP antagonist impaired NMDA-induced vasodilations in slices, it did not alter the hyperemic response to sensory stimulation. This difference between ex vivo and in vivo NVC responses is probably because bath application of NMDA recruits more massively NMDA receptors than sensory stimuli, resulting in enhanced PgI 2 biosynthesis and release. In addition, the levels of 6-keto PgF 1␣ released in slices are very low; it is therefore likely that the production of PgI 2 induced by sensory stimulation in vivo is negligible.
Conclusion
Using different multidisciplinary approaches we demonstrate that pyramidal cells produce and release COX-2-derived PgE 2 inducing vasodilation and functional hyperemia via activation of EP2 and EP4 receptors. So far most studies focused almost exclusively on the role of astrocytes in NVC thereby overlooking the possibility of a direct neurogenic control. Our finding emphasizing the importance of neurons provides important insights in the field of NVC and will have consequences on the interpretation of functional imaging based on hemodynamic signals widely used to map neuronal activity in health and disease.
